论文部分内容阅读
双时相门冬胰岛素30(BIAsp30)较预混人胰岛素能够更好地模拟生理性胰岛素的分泌,起效快、峰值高,可有效控制空腹和餐后血糖,减少低血糖发生。2011年新版药品说明书的更新,明确了BIAsp30可用于10岁及以上的儿童青少年及老年糖尿病患者,并且可实现一针安全起始到三针强化治疗的灵活转换。BIAsp30由于兼顾了有效性、安全性及灵活性,利用“一种制剂、一种注射装置”实现了更广泛的临床应用。
Compared with pre-mixed insulin, BIAsp30 can simulate the secretion of physiological insulin better, with rapid onset and high peak value, which can effectively control fasting and postprandial blood glucose and reduce hypoglycemia. The update to the 2011 version of the new drug specification makes it clear that BIAsp30 can be used in children and adolescents with diabetes 10 years and older and elderly patients with diabetes and can achieve a one-shot, flexible start-up to three-needle intensive conversion. BIAsp30 utilizes a “one formulation, one injection device” for a broader range of clinical applications because of its effectiveness, safety and flexibility.